Oncology Benchmarks Reveal That Trial Duration is Low-Impact Clinical Cost Driver

Data show a low correlation between trial duration and total cost in Phase 2 oncology trials

RESEARCH TRIANGLE PARK, N.C.--()--As with patient enrollment, trial duration impacts Phase 2 oncology trials’ expenses. But longer trials do not have necessarily come with large overruns or tremendous costs.

“Many factors contribute to trial duration — chief among them is patient recruitment,” said Ryan McGuire, research team leader at Cutting Edge Information, a leading clinical operations benchmarking firm. “The rarer a disease, the more difficult it is to find and recruit patients for a trial. The more restrictive the required patient profile, the harder it is to recruit patients, which often leads to longer durations.”

A recent study by Cutting Edge Information, “Oncology Clinical Trials: Drug Development Resources and Case Studies” examines oncology trials’ length of time to completion. The durations for Phase 2 trials, in particular, ranged from 12 to 48 months. Among those trials, the average duration was 26.1 months.

According to the research, trial duration does not contribute to total costs for oncology studies as significantly as patient recruitment. The correlation between trial duration and total cost in Phase 2 oncology trials is low. The data reveal, with the exception of two large pharmaceutical companies, only a slight increase in costs as durations increase. Consequently, these exceptions had the highest patient enrollments among all Phase 2 trials examined.

The study also examined the cost per patient per month for surveyed Phase 2 trials. The average cost per patient per month among the trials is $3,900. Two examined companies reported the highest cost per patient per month at $7,500 and $7,700, respectively.

“Oncology Clinical Trials: Drug Development Resources and Case Studies” (http://www.cuttingedgeinfo.com/research/clinical-development/oncology-clinical-trials/) details oncology clinical development data, including specific best practices and strategies for allocating clinical development resources. Drug companies that manufacture oncology medicines can use this report to:

  • Explore areas of higher activity for different types of cancer drug development.
  • Determine the per-patient cost and other critical cost drivers for different types of oncology clinical trials.
  • Compare the predicted and actual patient enrollment metrics of 30 oncology clinical trials from Phase 1 to Phase 3.

For more information about clinical research associate benchmarks, contact Cassie Demeter at 919-403-6583.

Contacts

Cutting Edge Information
Cassie Demeter, 919-403-6583

Release Summary

Data show a low correlation between trial duration and total cost in Phase 2 oncology trials.

Sharing

Contacts

Cutting Edge Information
Cassie Demeter, 919-403-6583